ad image

ViiV Healthcare

1 / 1
GSK
HIV

ViiV Healthcare’s Injectable Formulation Dosed Every Two Months Shows Higher Efficacy than Daily Oral PrEP

GSK

PR-M05-20-NI-034-1543May 22, 2020
GSK
HIV Treatment

ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-treatment Regimen Administered Every Two Months

GSK

PR-M08-19-NI-074Aug 26, 2019
GSK’s ViiV Healthcare Seeks FDA Approval for Combination HIV Therapy
FDA Approval

GSK’s ViiV Healthcare Seeks FDA Approval for Combination HIV Therapy

Emilie Branch

Pharma's Almanac

PAO-M10-18-NI-029Oct 29, 2018
1 / 1